Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Clinical trial NCT02674061 · COMPLETED
Trial details
- NCT number
- NCT02674061
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-25
- Primary completion
- 2019-09-18
- Enrollment
- 376
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.